KaliVir Immunotherapeutics
KaliVir Immunotherapeutics was founded in 2019 to pioneer a unique and novel approach to cancer treatment.
Pittsburgh, United States
43 employees
Series A
Health Care, Health and Wellness +1
General Information
Get notified when KaliVir Immunotherapeutics moves
Funding, new markets, leadership changes, hiring surges — one e-mail, only when something happens.
Track KaliVir Immunotherapeutics
Get real-time alerts for funding, hiring, news, and 40+ signal types.
See how it worksDiscover More
United States Market
Health Care
About KaliVir Immunotherapeutics
Taxonomy: Immunotherapy, Cancer treatment, Oncolytic viral therapy, Cancer cell targeting, Virotherapy, Oncolytic virus research, University collaboration, Tumor targeting, Next-generation therapy
Funding Rounds & Investors (1)
View All| Funding Stage | Amount | Investors | Lead Investors | Date |
|---|---|---|---|---|
| Series A | •••••• | 4 |
|
16 Mar 2022 |
KaliVir Immunotherapeutics Alternatives & Competitors
Seneca Therapeutics is developing a novel cancer therapy (oncolytic immunotherapeutic) for patients...
We make cancer immunotherapies more powerful.
Developing oncolytic viruses as therapeutics for cancer
FAQ About KaliVir Immunotherapeutics
Don't just browse. Track.
Signal Tracker monitors KaliVir Immunotherapeutics and millions of companies for funding rounds, hiring surges, product changes, and 40+ signal types — so you never miss an opportunity.
